Investments
35Portfolio Exits
19Latest Wasatch Advisors News
Mar 7, 2022
Investor Karakoram has offloaded total 72,94,115 equity shares in the company at an average price of Rs 425.75 per share, as per the bulk deals data. Trade × India-focussed private equity firm Kedaara-owned Karakoram has sold 7.1 percent equity stake in diagnostic chain Vijaya Diagnostic Centre via open market transactions on March 7. Investor Karakoram has offloaded total 72,94,115 equity shares in the company at an average price of Rs 425.75 per share, as per the bulk deals data. At the end of December 2021, Karakoram held 9.64 percent shareholding or 98.29 lakh shares in Vijaya Diagnostic Centre . However, the 95 percent of shares sold by Karakoram has been bought by three investors AL Mehwar Commercial Investments LLC, Destinations International EQ Fund, and Wasatch Advisors Inc. AL Mehwar Commercial Investments LLC acquired 20,35,857 equity shares, Destinations International EQ Fund A Series of Brinker Capital Destinations Trust bought 8,94,610 equity shares, and Wasatch Advisors Inc through its funds - Wasatch Emerging India Fund and Wasatch International Opportunities Fund - purchased 40.1 lakh equity shares in Vijaya Diagnostic. These shares were bought at an average price of Rs 425.75 per share.
Wasatch Advisors Investments
35 Investments
Wasatch Advisors has made 35 investments. Their latest investment was in Medallia as part of their Series F on February 2, 2019.
Wasatch Advisors Investments Activity
Date | Round | Company | Amount | New? | Co-Investors | Sources |
|---|---|---|---|---|---|---|
2/27/2019 | Series F | Medallia | $70M | Yes | 3 | |
5/12/2015 | Series F | DocuSign | $233M | Yes | 36 | |
5/1/2015 | Series A | iVeena Delivery Systems | $1.3M | Yes | 2 | |
9/4/2014 | Series E | |||||
9/23/2010 | Series C - II |
Date | 2/27/2019 | 5/12/2015 | 5/1/2015 | 9/4/2014 | 9/23/2010 |
|---|---|---|---|---|---|
Round | Series F | Series F | Series A | Series E | Series C - II |
Company | Medallia | DocuSign | iVeena Delivery Systems | ||
Amount | $70M | $233M | $1.3M | ||
New? | Yes | Yes | Yes | ||
Co-Investors | |||||
Sources | 3 | 36 | 2 |
Wasatch Advisors Portfolio Exits
19 Portfolio Exits
Wasatch Advisors has 19 portfolio exits. Their latest portfolio exit was Endologix on October 01, 2020.
Date | Exit | Companies | Valuation Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model. | Acquirer | Sources |
|---|---|---|---|---|---|
10/1/2020 | Take Private | 3 | |||
7/19/2019 | IPO | 2 | |||
4/27/2018 | IPO | 7 | |||
Wasatch Advisors Team
3 Team Members
Wasatch Advisors has 3 team members, including current Managing Director, Karey Barker.
Name | Work History | Title | Status |
|---|---|---|---|
Karey Barker | Managing Director | Current | |
Eugene Podsiadlo | Managing Director | Current | |
Greg Bohlen | Morgan Creek Capital Management, Transoma Medical, Cross Creek, and UBS Investment Bank | Managing Director | Former |
Name | Karey Barker | Eugene Podsiadlo | Greg Bohlen |
|---|---|---|---|
Work History | Morgan Creek Capital Management, Transoma Medical, Cross Creek, and UBS Investment Bank | ||
Title | Managing Director | Managing Director | Managing Director |
Status | Current | Current | Former |
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.